Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and ...

Nammi Therapeutics, Inc. Announces First Patient Dosed with ...

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma.

Nammi Therapeutics doses first subject in trial of QXL138AM for ...

In Part B, the study will expand to dose cohorts with two solid tumour indications and multiple myeloma. The primary endpoints will assess ...

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors ...

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma. ... Description. Study QXL138AM-001 is a Phase 1a/1b study to ...

Usmani Projects a Future of CAR T in Community for Myeloma and ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and multiple ...

Nammi Therapeutics doses first subject in trial of QXL138AM for ...

In Part B, the study will expand to dose cohorts with two solid tumour indications and multiple myeloma. The primary endpoints will assess ...

Advances Clinical Development of Lead Program, QXL138AM - MMRF

... study of their lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma.

QXL138AM / Nammi Therap - Larvol Delta

... study of our lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. QXL138AM is a ...

Condition: Solid Tumors or Multiple Myeloma - Research Trials

Condition: Solid Tumors or Multiple Myeloma. Sponsor: Nammi Therapeutics Inc. Full Title
Protocol QXL138AM-001: A First-in-human Phase 1a/1b ...

Nammi Therapeutics Secures Series B Funding from MMRF's ...

... solid tumors and multiple myeloma. QXL138AM is a novel Masked ... multiple myeloma research. All profits are reinvested into research ...

News - Nammi Therapeutics

... trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM ... Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the ...

Clinical Trial Finder Tool - Multiple Myeloma Research Foundation

... multiple myeloma, using a metformin-extended release medication ... Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma.

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors ...

Condition: Solid Tumors or Multiple Myeloma. Sponsor: Nammi Therapeutics Inc. Full Title Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to ...

Novel Immunotherapy QXL138AM Wins Orphan Drug Status in US

... QXL138AM immunotherapy for multiple myeloma ... solid tumors. Print This Page. About the Author. Marta Figueiredo, PhD avatar. Marta ...

Nammi Therapeutics, Inc. Completes Series B Round with ...

... study of our lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma.

News and Updates From the Myeloma Investment Fund®

... study of their lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. Read more... July ...

Our Research Trials - New York Cancer & Blood Specialists

Phase 1 Study of SGN-B6A in Advanced Solid Tumors ... QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma ...

Send My Information - ResearchMatch

"Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma". If you are interested in learning more about this trial ...

Nammi Therapeutics Granted FDA Orphan Drug Designation For ...

... QXL138AM for the Treatment of Multiple Myeloma. June 13 ... CD138 is expressed in multiple myeloma as well as many different solid tumor ...

Multiple Myeloma Clinical Trials - SparkCures

We help myeloma patients find, understand and connect with their clinical trial options at centers around the US.